nodes	percent_of_prediction	percent_of_DWPC	metapath
Repaglinide—CYP3A4—prostate cancer	0.144	1	CbGaD
Repaglinide—SLCO1B1—Cabazitaxel—prostate cancer	0.056	0.0995	CbGbCtD
Repaglinide—SLCO1B1—Estrone—prostate cancer	0.0547	0.0973	CbGbCtD
Repaglinide—ALB—Abiraterone—prostate cancer	0.0415	0.0737	CbGbCtD
Repaglinide—CYP2C8—Nilutamide—prostate cancer	0.0387	0.0687	CbGbCtD
Repaglinide—SLCO1B1—Conjugated Estrogens—prostate cancer	0.0358	0.0636	CbGbCtD
Repaglinide—CYP2C8—Abiraterone—prostate cancer	0.032	0.0569	CbGbCtD
Repaglinide—SLCO1B1—Estradiol—prostate cancer	0.0314	0.0559	CbGbCtD
Repaglinide—ALB—Estrone—prostate cancer	0.03	0.0533	CbGbCtD
Repaglinide—CYP3A4—Estradiol valerate/Dienogest—prostate cancer	0.0299	0.053	CbGbCtD
Repaglinide—CYP2C8—Cabazitaxel—prostate cancer	0.0237	0.0421	CbGbCtD
Repaglinide—CYP2C8—Ethinyl Estradiol—prostate cancer	0.0206	0.0367	CbGbCtD
Repaglinide—ALB—Estradiol—prostate cancer	0.0172	0.0306	CbGbCtD
Repaglinide—CYP3A4—Bicalutamide—prostate cancer	0.0157	0.0279	CbGbCtD
Repaglinide—ALB—Prednisone—prostate cancer	0.0148	0.0263	CbGbCtD
Repaglinide—CYP3A4—Estramustine—prostate cancer	0.0146	0.0259	CbGbCtD
Repaglinide—CYP2C8—Estradiol—prostate cancer	0.0133	0.0236	CbGbCtD
Repaglinide—CYP3A4—Abiraterone—prostate cancer	0.013	0.0231	CbGbCtD
Repaglinide—CYP3A4—Flutamide—prostate cancer	0.013	0.0231	CbGbCtD
Repaglinide—CYP3A4—Cabazitaxel—prostate cancer	0.00961	0.0171	CbGbCtD
Repaglinide—CYP3A4—Estrone—prostate cancer	0.0094	0.0167	CbGbCtD
Repaglinide—CYP2C8—Etoposide—prostate cancer	0.00869	0.0154	CbGbCtD
Repaglinide—ABCC8—penis—prostate cancer	0.0085	0.305	CbGeAlD
Repaglinide—CYP3A4—Ethinyl Estradiol—prostate cancer	0.00837	0.0149	CbGbCtD
Repaglinide—CYP3A4—Conjugated Estrogens—prostate cancer	0.00615	0.0109	CbGbCtD
Repaglinide—CYP3A4—Mitoxantrone—prostate cancer	0.00559	0.00993	CbGbCtD
Repaglinide—CYP3A4—Estradiol—prostate cancer	0.0054	0.00959	CbGbCtD
Repaglinide—CYP3A4—Prednisone—prostate cancer	0.00464	0.00824	CbGbCtD
Repaglinide—CYP3A4—Etoposide—prostate cancer	0.00352	0.00626	CbGbCtD
Repaglinide—CYP3A4—Docetaxel—prostate cancer	0.00322	0.00573	CbGbCtD
Repaglinide—CYP3A4—Doxorubicin—prostate cancer	0.0024	0.00427	CbGbCtD
Repaglinide—ABCC8—prostate gland—prostate cancer	0.00203	0.0729	CbGeAlD
Repaglinide—CYP3A4—urine—prostate cancer	0.00193	0.0692	CbGeAlD
Repaglinide—PPARG—Teniposide—Etoposide—prostate cancer	0.00174	1	CbGdCrCtD
Repaglinide—ABCC8—seminal vesicle—prostate cancer	0.00172	0.0616	CbGeAlD
Repaglinide—PPARG—prostate gland—prostate cancer	0.00155	0.0556	CbGeAlD
Repaglinide—ABCC8—renal system—prostate cancer	0.00138	0.0497	CbGeAlD
Repaglinide—SLCO1B1—renal system—prostate cancer	0.00123	0.0439	CbGeAlD
Repaglinide—PPARG—epithelium—prostate cancer	0.00114	0.0409	CbGeAlD
Repaglinide—PPARG—renal system—prostate cancer	0.00106	0.0379	CbGeAlD
Repaglinide—PPARG—urethra—prostate cancer	0.00104	0.0372	CbGeAlD
Repaglinide—ABCC8—testis—prostate cancer	0.000895	0.0321	CbGeAlD
Repaglinide—PPARG—bone marrow—prostate cancer	0.000799	0.0287	CbGeAlD
Repaglinide—KCNJ11—lymph node—prostate cancer	0.000704	0.0253	CbGeAlD
Repaglinide—CYP2C8—renal system—prostate cancer	0.000697	0.025	CbGeAlD
Repaglinide—PPARG—testis—prostate cancer	0.000683	0.0245	CbGeAlD
Repaglinide—ALB—testis—prostate cancer	0.000641	0.023	CbGeAlD
Repaglinide—PPARG—lymph node—prostate cancer	0.000495	0.0178	CbGeAlD
Repaglinide—CYP3A4—renal system—prostate cancer	0.000472	0.0169	CbGeAlD
Repaglinide—ALB—lymph node—prostate cancer	0.000464	0.0167	CbGeAlD
Repaglinide—CYP2C8—testis—prostate cancer	0.00045	0.0162	CbGeAlD
Repaglinide—Myocardial infarction—Prednisone—prostate cancer	0.000128	0.000806	CcSEcCtD
Repaglinide—Leukopenia—Etoposide—prostate cancer	0.000127	0.000803	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	0.000127	0.000802	CcSEcCtD
Repaglinide—Eye disorder—Docetaxel—prostate cancer	0.000127	0.0008	CcSEcCtD
Repaglinide—Visual impairment—Capecitabine—prostate cancer	0.000127	0.000799	CcSEcCtD
Repaglinide—Anaphylactoid reaction—Doxorubicin—prostate cancer	0.000126	0.000798	CcSEcCtD
Repaglinide—Cardiac disorder—Docetaxel—prostate cancer	0.000126	0.000795	CcSEcCtD
Repaglinide—Hypoglycaemia—Doxorubicin—prostate cancer	0.000125	0.000792	CcSEcCtD
Repaglinide—Paraesthesia—Mitoxantrone—prostate cancer	0.000125	0.00079	CcSEcCtD
Repaglinide—Erythema multiforme—Capecitabine—prostate cancer	0.000124	0.000784	CcSEcCtD
Repaglinide—Eye disorder—Capecitabine—prostate cancer	0.000123	0.000775	CcSEcCtD
Repaglinide—Dyspepsia—Mitoxantrone—prostate cancer	0.000123	0.000775	CcSEcCtD
Repaglinide—Hypertension—Etoposide—prostate cancer	0.000123	0.000774	CcSEcCtD
Repaglinide—Immune system disorder—Docetaxel—prostate cancer	0.000122	0.000773	CcSEcCtD
Repaglinide—Gastrointestinal pain—Estradiol—prostate cancer	0.000122	0.000772	CcSEcCtD
Repaglinide—Cardiac disorder—Capecitabine—prostate cancer	0.000122	0.000769	CcSEcCtD
Repaglinide—Arrhythmia—Docetaxel—prostate cancer	0.000121	0.000765	CcSEcCtD
Repaglinide—Chest pain—Etoposide—prostate cancer	0.000121	0.000764	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—prostate cancer	0.00012	0.000758	CcSEcCtD
Repaglinide—Vomiting—Goserelin—prostate cancer	0.00012	0.000758	CcSEcCtD
Repaglinide—Alopecia—Docetaxel—prostate cancer	0.00012	0.000757	CcSEcCtD
Repaglinide—Constipation—Mitoxantrone—prostate cancer	0.000119	0.000753	CcSEcCtD
Repaglinide—Rash—Goserelin—prostate cancer	0.000119	0.000751	CcSEcCtD
Repaglinide—Dermatitis—Goserelin—prostate cancer	0.000119	0.000751	CcSEcCtD
Repaglinide—Vomiting—Conjugated Estrogens—prostate cancer	0.000119	0.00075	CcSEcCtD
Repaglinide—Urticaria—Estradiol—prostate cancer	0.000119	0.00075	CcSEcCtD
Repaglinide—Immune system disorder—Capecitabine—prostate cancer	0.000119	0.000749	CcSEcCtD
Repaglinide—Abdominal pain—Estradiol—prostate cancer	0.000118	0.000747	CcSEcCtD
Repaglinide—Headache—Goserelin—prostate cancer	0.000118	0.000746	CcSEcCtD
Repaglinide—Malnutrition—Docetaxel—prostate cancer	0.000118	0.000745	CcSEcCtD
Repaglinide—Erythema—Docetaxel—prostate cancer	0.000118	0.000745	CcSEcCtD
Repaglinide—Rash—Conjugated Estrogens—prostate cancer	0.000118	0.000744	CcSEcCtD
Repaglinide—Dermatitis—Conjugated Estrogens—prostate cancer	0.000118	0.000743	CcSEcCtD
Repaglinide—Arrhythmia—Capecitabine—prostate cancer	0.000117	0.000741	CcSEcCtD
Repaglinide—Headache—Conjugated Estrogens—prostate cancer	0.000117	0.000739	CcSEcCtD
Repaglinide—Alopecia—Capecitabine—prostate cancer	0.000116	0.000733	CcSEcCtD
Repaglinide—Anaphylactic shock—Etoposide—prostate cancer	0.000116	0.000732	CcSEcCtD
Repaglinide—Erythema—Capecitabine—prostate cancer	0.000114	0.000722	CcSEcCtD
Repaglinide—Malnutrition—Capecitabine—prostate cancer	0.000114	0.000722	CcSEcCtD
Repaglinide—Back pain—Docetaxel—prostate cancer	0.000114	0.000721	CcSEcCtD
Repaglinide—Gastrointestinal pain—Mitoxantrone—prostate cancer	0.000114	0.00072	CcSEcCtD
Repaglinide—Thrombocytopenia—Etoposide—prostate cancer	0.000114	0.000717	CcSEcCtD
Repaglinide—Skin disorder—Etoposide—prostate cancer	0.000113	0.000711	CcSEcCtD
Repaglinide—Nausea—Goserelin—prostate cancer	0.000112	0.000708	CcSEcCtD
Repaglinide—Pancreatitis—Epirubicin—prostate cancer	0.000112	0.000707	CcSEcCtD
Repaglinide—Angina pectoris—Epirubicin—prostate cancer	0.000111	0.000703	CcSEcCtD
Repaglinide—Nausea—Conjugated Estrogens—prostate cancer	0.000111	0.000701	CcSEcCtD
Repaglinide—Urticaria—Mitoxantrone—prostate cancer	0.000111	0.000699	CcSEcCtD
Repaglinide—Back pain—Capecitabine—prostate cancer	0.000111	0.000698	CcSEcCtD
Repaglinide—Hypersensitivity—Estradiol—prostate cancer	0.00011	0.000696	CcSEcCtD
Repaglinide—Abdominal pain—Mitoxantrone—prostate cancer	0.00011	0.000696	CcSEcCtD
Repaglinide—Bronchitis—Epirubicin—prostate cancer	0.00011	0.000694	CcSEcCtD
Repaglinide—Eye disorder—Prednisone—prostate cancer	0.000109	0.00069	CcSEcCtD
Repaglinide—Pruritus—Estradiol—prostate cancer	0.000106	0.000668	CcSEcCtD
Repaglinide—Leukopenia—Docetaxel—prostate cancer	0.000106	0.000667	CcSEcCtD
Repaglinide—Immune system disorder—Prednisone—prostate cancer	0.000106	0.000667	CcSEcCtD
Repaglinide—Arrhythmia—Prednisone—prostate cancer	0.000104	0.00066	CcSEcCtD
Repaglinide—Palpitations—Docetaxel—prostate cancer	0.000104	0.000659	CcSEcCtD
Repaglinide—Paraesthesia—Etoposide—prostate cancer	0.000104	0.000657	CcSEcCtD
Repaglinide—Pancreatitis—Doxorubicin—prostate cancer	0.000104	0.000655	CcSEcCtD
Repaglinide—Alopecia—Prednisone—prostate cancer	0.000103	0.000653	CcSEcCtD
Repaglinide—Hyperglycaemia—Epirubicin—prostate cancer	0.000103	0.000651	CcSEcCtD
Repaglinide—Angina pectoris—Doxorubicin—prostate cancer	0.000103	0.00065	CcSEcCtD
Repaglinide—Hypersensitivity—Mitoxantrone—prostate cancer	0.000103	0.000648	CcSEcCtD
Repaglinide—Diarrhoea—Estradiol—prostate cancer	0.000102	0.000646	CcSEcCtD
Repaglinide—Leukopenia—Capecitabine—prostate cancer	0.000102	0.000646	CcSEcCtD
Repaglinide—Hypertension—Docetaxel—prostate cancer	0.000102	0.000644	CcSEcCtD
Repaglinide—Malnutrition—Prednisone—prostate cancer	0.000102	0.000643	CcSEcCtD
Repaglinide—Erythema—Prednisone—prostate cancer	0.000102	0.000643	CcSEcCtD
Repaglinide—Bronchitis—Doxorubicin—prostate cancer	0.000102	0.000642	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Epirubicin—prostate cancer	0.000101	0.000638	CcSEcCtD
Repaglinide—Palpitations—Capecitabine—prostate cancer	0.000101	0.000638	CcSEcCtD
Repaglinide—Chest pain—Docetaxel—prostate cancer	0.000101	0.000635	CcSEcCtD
Repaglinide—Arthralgia—Docetaxel—prostate cancer	0.000101	0.000635	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Etoposide—prostate cancer	0.0001	0.000632	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—prostate cancer	9.98e-05	0.00063	CcSEcCtD
Repaglinide—Jaundice—Epirubicin—prostate cancer	9.93e-05	0.000627	CcSEcCtD
Repaglinide—Constipation—Etoposide—prostate cancer	9.91e-05	0.000626	CcSEcCtD
Repaglinide—Urinary tract infection—Epirubicin—prostate cancer	9.9e-05	0.000625	CcSEcCtD
Repaglinide—Hypertension—Capecitabine—prostate cancer	9.87e-05	0.000623	CcSEcCtD
Repaglinide—Arthralgia—Capecitabine—prostate cancer	9.73e-05	0.000614	CcSEcCtD
Repaglinide—Chest pain—Capecitabine—prostate cancer	9.73e-05	0.000614	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—prostate cancer	9.66e-05	0.00061	CcSEcCtD
Repaglinide—Hepatobiliary disease—Epirubicin—prostate cancer	9.64e-05	0.000608	CcSEcCtD
Repaglinide—Oedema—Docetaxel—prostate cancer	9.63e-05	0.000608	CcSEcCtD
Repaglinide—Anaphylactic shock—Docetaxel—prostate cancer	9.63e-05	0.000608	CcSEcCtD
Repaglinide—Sinusitis—Epirubicin—prostate cancer	9.56e-05	0.000604	CcSEcCtD
Repaglinide—Hyperglycaemia—Doxorubicin—prostate cancer	9.54e-05	0.000602	CcSEcCtD
Repaglinide—Diarrhoea—Mitoxantrone—prostate cancer	9.54e-05	0.000602	CcSEcCtD
Repaglinide—Vomiting—Estradiol—prostate cancer	9.51e-05	0.000601	CcSEcCtD
Repaglinide—Gastrointestinal pain—Etoposide—prostate cancer	9.48e-05	0.000599	CcSEcCtD
Repaglinide—Thrombocytopenia—Docetaxel—prostate cancer	9.43e-05	0.000596	CcSEcCtD
Repaglinide—Rash—Estradiol—prostate cancer	9.43e-05	0.000596	CcSEcCtD
Repaglinide—Dermatitis—Estradiol—prostate cancer	9.42e-05	0.000595	CcSEcCtD
Repaglinide—Headache—Estradiol—prostate cancer	9.37e-05	0.000592	CcSEcCtD
Repaglinide—Skin disorder—Docetaxel—prostate cancer	9.36e-05	0.000591	CcSEcCtD
Repaglinide—Stevens-Johnson syndrome—Doxorubicin—prostate cancer	9.35e-05	0.00059	CcSEcCtD
Repaglinide—Oedema—Capecitabine—prostate cancer	9.33e-05	0.000589	CcSEcCtD
Repaglinide—Urticaria—Etoposide—prostate cancer	9.21e-05	0.000582	CcSEcCtD
Repaglinide—Jaundice—Doxorubicin—prostate cancer	9.19e-05	0.00058	CcSEcCtD
Repaglinide—Rhinitis—Epirubicin—prostate cancer	9.17e-05	0.000579	CcSEcCtD
Repaglinide—Abdominal pain—Etoposide—prostate cancer	9.16e-05	0.000579	CcSEcCtD
Repaglinide—Urinary tract infection—Doxorubicin—prostate cancer	9.16e-05	0.000579	CcSEcCtD
Repaglinide—Hepatitis—Epirubicin—prostate cancer	9.15e-05	0.000578	CcSEcCtD
Repaglinide—Thrombocytopenia—Capecitabine—prostate cancer	9.13e-05	0.000577	CcSEcCtD
Repaglinide—Skin disorder—Capecitabine—prostate cancer	9.06e-05	0.000572	CcSEcCtD
Repaglinide—Oedema peripheral—Epirubicin—prostate cancer	9.01e-05	0.000569	CcSEcCtD
Repaglinide—Hepatobiliary disease—Doxorubicin—prostate cancer	8.92e-05	0.000563	CcSEcCtD
Repaglinide—Nausea—Estradiol—prostate cancer	8.88e-05	0.000561	CcSEcCtD
Repaglinide—Vomiting—Mitoxantrone—prostate cancer	8.86e-05	0.00056	CcSEcCtD
Repaglinide—Sinusitis—Doxorubicin—prostate cancer	8.84e-05	0.000559	CcSEcCtD
Repaglinide—Visual impairment—Epirubicin—prostate cancer	8.81e-05	0.000557	CcSEcCtD
Repaglinide—Hypertension—Prednisone—prostate cancer	8.79e-05	0.000555	CcSEcCtD
Repaglinide—Rash—Mitoxantrone—prostate cancer	8.79e-05	0.000555	CcSEcCtD
Repaglinide—Dermatitis—Mitoxantrone—prostate cancer	8.78e-05	0.000554	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Docetaxel—prostate cancer	8.78e-05	0.000554	CcSEcCtD
Repaglinide—Headache—Mitoxantrone—prostate cancer	8.73e-05	0.000551	CcSEcCtD
Repaglinide—Arthralgia—Prednisone—prostate cancer	8.67e-05	0.000547	CcSEcCtD
Repaglinide—Paraesthesia—Docetaxel—prostate cancer	8.65e-05	0.000546	CcSEcCtD
Repaglinide—Erythema multiforme—Epirubicin—prostate cancer	8.65e-05	0.000546	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—prostate cancer	8.61e-05	0.000544	CcSEcCtD
Repaglinide—Eye disorder—Epirubicin—prostate cancer	8.55e-05	0.00054	CcSEcCtD
Repaglinide—Hypersensitivity—Etoposide—prostate cancer	8.54e-05	0.000539	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Capecitabine—prostate cancer	8.5e-05	0.000537	CcSEcCtD
Repaglinide—Cardiac disorder—Epirubicin—prostate cancer	8.49e-05	0.000536	CcSEcCtD
Repaglinide—Rhinitis—Doxorubicin—prostate cancer	8.48e-05	0.000536	CcSEcCtD
Repaglinide—Dyspepsia—Docetaxel—prostate cancer	8.48e-05	0.000536	CcSEcCtD
Repaglinide—Hepatitis—Doxorubicin—prostate cancer	8.46e-05	0.000534	CcSEcCtD
Repaglinide—Paraesthesia—Capecitabine—prostate cancer	8.38e-05	0.000529	CcSEcCtD
Repaglinide—Oedema peripheral—Doxorubicin—prostate cancer	8.34e-05	0.000526	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Docetaxel—prostate cancer	8.32e-05	0.000525	CcSEcCtD
Repaglinide—Anaphylactic shock—Prednisone—prostate cancer	8.31e-05	0.000525	CcSEcCtD
Repaglinide—Oedema—Prednisone—prostate cancer	8.31e-05	0.000525	CcSEcCtD
Repaglinide—Nausea—Mitoxantrone—prostate cancer	8.28e-05	0.000523	CcSEcCtD
Repaglinide—Immune system disorder—Epirubicin—prostate cancer	8.26e-05	0.000522	CcSEcCtD
Repaglinide—Constipation—Docetaxel—prostate cancer	8.24e-05	0.00052	CcSEcCtD
Repaglinide—Dyspepsia—Capecitabine—prostate cancer	8.21e-05	0.000518	CcSEcCtD
Repaglinide—Pruritus—Etoposide—prostate cancer	8.2e-05	0.000518	CcSEcCtD
Repaglinide—Arrhythmia—Epirubicin—prostate cancer	8.17e-05	0.000516	CcSEcCtD
Repaglinide—Visual impairment—Doxorubicin—prostate cancer	8.16e-05	0.000515	CcSEcCtD
Repaglinide—Alopecia—Epirubicin—prostate cancer	8.08e-05	0.00051	CcSEcCtD
Repaglinide—Skin disorder—Prednisone—prostate cancer	8.07e-05	0.00051	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Capecitabine—prostate cancer	8.05e-05	0.000509	CcSEcCtD
Repaglinide—Erythema multiforme—Doxorubicin—prostate cancer	8e-05	0.000505	CcSEcCtD
Repaglinide—Constipation—Capecitabine—prostate cancer	7.98e-05	0.000504	CcSEcCtD
Repaglinide—Erythema—Epirubicin—prostate cancer	7.96e-05	0.000503	CcSEcCtD
Repaglinide—Malnutrition—Epirubicin—prostate cancer	7.96e-05	0.000503	CcSEcCtD
Repaglinide—Diarrhoea—Etoposide—prostate cancer	7.93e-05	0.000501	CcSEcCtD
Repaglinide—Eye disorder—Doxorubicin—prostate cancer	7.91e-05	0.000499	CcSEcCtD
Repaglinide—Gastrointestinal pain—Docetaxel—prostate cancer	7.88e-05	0.000497	CcSEcCtD
Repaglinide—Cardiac disorder—Doxorubicin—prostate cancer	7.85e-05	0.000496	CcSEcCtD
Repaglinide—Back pain—Epirubicin—prostate cancer	7.7e-05	0.000486	CcSEcCtD
Repaglinide—Immune system disorder—Doxorubicin—prostate cancer	7.64e-05	0.000483	CcSEcCtD
Repaglinide—Gastrointestinal pain—Capecitabine—prostate cancer	7.63e-05	0.000482	CcSEcCtD
Repaglinide—Abdominal pain—Docetaxel—prostate cancer	7.62e-05	0.000481	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Prednisone—prostate cancer	7.57e-05	0.000478	CcSEcCtD
Repaglinide—Arrhythmia—Doxorubicin—prostate cancer	7.56e-05	0.000477	CcSEcCtD
Repaglinide—Alopecia—Doxorubicin—prostate cancer	7.48e-05	0.000472	CcSEcCtD
Repaglinide—Paraesthesia—Prednisone—prostate cancer	7.46e-05	0.000471	CcSEcCtD
Repaglinide—Urticaria—Capecitabine—prostate cancer	7.41e-05	0.000468	CcSEcCtD
Repaglinide—Abdominal pain—Capecitabine—prostate cancer	7.37e-05	0.000466	CcSEcCtD
Repaglinide—Vomiting—Etoposide—prostate cancer	7.37e-05	0.000465	CcSEcCtD
Repaglinide—Erythema—Doxorubicin—prostate cancer	7.37e-05	0.000465	CcSEcCtD
Repaglinide—Malnutrition—Doxorubicin—prostate cancer	7.37e-05	0.000465	CcSEcCtD
Repaglinide—Dyspepsia—Prednisone—prostate cancer	7.31e-05	0.000462	CcSEcCtD
Repaglinide—Rash—Etoposide—prostate cancer	7.31e-05	0.000462	CcSEcCtD
Repaglinide—Dermatitis—Etoposide—prostate cancer	7.3e-05	0.000461	CcSEcCtD
Repaglinide—Headache—Etoposide—prostate cancer	7.26e-05	0.000459	CcSEcCtD
Repaglinide—Leukopenia—Epirubicin—prostate cancer	7.13e-05	0.00045	CcSEcCtD
Repaglinide—Back pain—Doxorubicin—prostate cancer	7.13e-05	0.00045	CcSEcCtD
Repaglinide—Constipation—Prednisone—prostate cancer	7.11e-05	0.000449	CcSEcCtD
Repaglinide—Hypersensitivity—Docetaxel—prostate cancer	7.1e-05	0.000448	CcSEcCtD
Repaglinide—Palpitations—Epirubicin—prostate cancer	7.04e-05	0.000444	CcSEcCtD
Repaglinide—Nausea—Etoposide—prostate cancer	6.89e-05	0.000435	CcSEcCtD
Repaglinide—Hypertension—Epirubicin—prostate cancer	6.87e-05	0.000434	CcSEcCtD
Repaglinide—Hypersensitivity—Capecitabine—prostate cancer	6.87e-05	0.000434	CcSEcCtD
Repaglinide—Pruritus—Docetaxel—prostate cancer	6.82e-05	0.00043	CcSEcCtD
Repaglinide—Gastrointestinal pain—Prednisone—prostate cancer	6.79e-05	0.000429	CcSEcCtD
Repaglinide—Chest pain—Epirubicin—prostate cancer	6.78e-05	0.000428	CcSEcCtD
Repaglinide—Arthralgia—Epirubicin—prostate cancer	6.78e-05	0.000428	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—prostate cancer	6.73e-05	0.000425	CcSEcCtD
Repaglinide—Urticaria—Prednisone—prostate cancer	6.6e-05	0.000417	CcSEcCtD
Repaglinide—Pruritus—Capecitabine—prostate cancer	6.6e-05	0.000417	CcSEcCtD
Repaglinide—Leukopenia—Doxorubicin—prostate cancer	6.59e-05	0.000416	CcSEcCtD
Repaglinide—Diarrhoea—Docetaxel—prostate cancer	6.59e-05	0.000416	CcSEcCtD
Repaglinide—Abdominal pain—Prednisone—prostate cancer	6.57e-05	0.000415	CcSEcCtD
Repaglinide—Palpitations—Doxorubicin—prostate cancer	6.51e-05	0.000411	CcSEcCtD
Repaglinide—Anaphylactic shock—Epirubicin—prostate cancer	6.5e-05	0.00041	CcSEcCtD
Repaglinide—Oedema—Epirubicin—prostate cancer	6.5e-05	0.00041	CcSEcCtD
Repaglinide—Diarrhoea—Capecitabine—prostate cancer	6.38e-05	0.000403	CcSEcCtD
Repaglinide—Thrombocytopenia—Epirubicin—prostate cancer	6.36e-05	0.000402	CcSEcCtD
Repaglinide—Hypertension—Doxorubicin—prostate cancer	6.36e-05	0.000402	CcSEcCtD
Repaglinide—Skin disorder—Epirubicin—prostate cancer	6.31e-05	0.000399	CcSEcCtD
Repaglinide—Chest pain—Doxorubicin—prostate cancer	6.27e-05	0.000396	CcSEcCtD
Repaglinide—Arthralgia—Doxorubicin—prostate cancer	6.27e-05	0.000396	CcSEcCtD
Repaglinide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—prostate cancer	6.23e-05	0.000393	CcSEcCtD
Repaglinide—Vomiting—Docetaxel—prostate cancer	6.13e-05	0.000387	CcSEcCtD
Repaglinide—Hypersensitivity—Prednisone—prostate cancer	6.12e-05	0.000387	CcSEcCtD
Repaglinide—Rash—Docetaxel—prostate cancer	6.07e-05	0.000384	CcSEcCtD
Repaglinide—Dermatitis—Docetaxel—prostate cancer	6.07e-05	0.000383	CcSEcCtD
Repaglinide—Headache—Docetaxel—prostate cancer	6.04e-05	0.000381	CcSEcCtD
Repaglinide—Anaphylactic shock—Doxorubicin—prostate cancer	6.01e-05	0.00038	CcSEcCtD
Repaglinide—Oedema—Doxorubicin—prostate cancer	6.01e-05	0.00038	CcSEcCtD
Repaglinide—Vomiting—Capecitabine—prostate cancer	5.93e-05	0.000375	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Epirubicin—prostate cancer	5.92e-05	0.000374	CcSEcCtD
Repaglinide—Thrombocytopenia—Doxorubicin—prostate cancer	5.89e-05	0.000372	CcSEcCtD
Repaglinide—Rash—Capecitabine—prostate cancer	5.88e-05	0.000371	CcSEcCtD
Repaglinide—Pruritus—Prednisone—prostate cancer	5.88e-05	0.000371	CcSEcCtD
Repaglinide—Dermatitis—Capecitabine—prostate cancer	5.88e-05	0.000371	CcSEcCtD
Repaglinide—Headache—Capecitabine—prostate cancer	5.84e-05	0.000369	CcSEcCtD
Repaglinide—Skin disorder—Doxorubicin—prostate cancer	5.84e-05	0.000369	CcSEcCtD
Repaglinide—Paraesthesia—Epirubicin—prostate cancer	5.84e-05	0.000368	CcSEcCtD
Repaglinide—Nausea—Docetaxel—prostate cancer	5.72e-05	0.000361	CcSEcCtD
Repaglinide—Dyspepsia—Epirubicin—prostate cancer	5.72e-05	0.000361	CcSEcCtD
Repaglinide—Diarrhoea—Prednisone—prostate cancer	5.69e-05	0.000359	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Epirubicin—prostate cancer	5.61e-05	0.000354	CcSEcCtD
Repaglinide—Constipation—Epirubicin—prostate cancer	5.56e-05	0.000351	CcSEcCtD
Repaglinide—Nausea—Capecitabine—prostate cancer	5.54e-05	0.00035	CcSEcCtD
Repaglinide—Musculoskeletal discomfort—Doxorubicin—prostate cancer	5.48e-05	0.000346	CcSEcCtD
Repaglinide—Paraesthesia—Doxorubicin—prostate cancer	5.4e-05	0.000341	CcSEcCtD
Repaglinide—Gastrointestinal pain—Epirubicin—prostate cancer	5.31e-05	0.000336	CcSEcCtD
Repaglinide—Dyspepsia—Doxorubicin—prostate cancer	5.29e-05	0.000334	CcSEcCtD
Repaglinide—Vomiting—Prednisone—prostate cancer	5.28e-05	0.000334	CcSEcCtD
Repaglinide—Rash—Prednisone—prostate cancer	5.24e-05	0.000331	CcSEcCtD
Repaglinide—Dermatitis—Prednisone—prostate cancer	5.23e-05	0.000331	CcSEcCtD
Repaglinide—Headache—Prednisone—prostate cancer	5.21e-05	0.000329	CcSEcCtD
Repaglinide—Gastrointestinal disorder—Doxorubicin—prostate cancer	5.19e-05	0.000328	CcSEcCtD
Repaglinide—Urticaria—Epirubicin—prostate cancer	5.16e-05	0.000326	CcSEcCtD
Repaglinide—Constipation—Doxorubicin—prostate cancer	5.14e-05	0.000325	CcSEcCtD
Repaglinide—Abdominal pain—Epirubicin—prostate cancer	5.14e-05	0.000324	CcSEcCtD
Repaglinide—Nausea—Prednisone—prostate cancer	4.94e-05	0.000312	CcSEcCtD
Repaglinide—Gastrointestinal pain—Doxorubicin—prostate cancer	4.92e-05	0.00031	CcSEcCtD
Repaglinide—Hypersensitivity—Epirubicin—prostate cancer	4.79e-05	0.000302	CcSEcCtD
Repaglinide—Urticaria—Doxorubicin—prostate cancer	4.78e-05	0.000302	CcSEcCtD
Repaglinide—Abdominal pain—Doxorubicin—prostate cancer	4.75e-05	0.0003	CcSEcCtD
Repaglinide—Pruritus—Epirubicin—prostate cancer	4.6e-05	0.00029	CcSEcCtD
Repaglinide—Diarrhoea—Epirubicin—prostate cancer	4.45e-05	0.000281	CcSEcCtD
Repaglinide—Hypersensitivity—Doxorubicin—prostate cancer	4.43e-05	0.00028	CcSEcCtD
Repaglinide—Pruritus—Doxorubicin—prostate cancer	4.25e-05	0.000269	CcSEcCtD
Repaglinide—Vomiting—Epirubicin—prostate cancer	4.13e-05	0.000261	CcSEcCtD
Repaglinide—Diarrhoea—Doxorubicin—prostate cancer	4.11e-05	0.00026	CcSEcCtD
Repaglinide—Rash—Epirubicin—prostate cancer	4.1e-05	0.000259	CcSEcCtD
Repaglinide—Dermatitis—Epirubicin—prostate cancer	4.09e-05	0.000258	CcSEcCtD
Repaglinide—Headache—Epirubicin—prostate cancer	4.07e-05	0.000257	CcSEcCtD
Repaglinide—Nausea—Epirubicin—prostate cancer	3.86e-05	0.000244	CcSEcCtD
Repaglinide—Vomiting—Doxorubicin—prostate cancer	3.82e-05	0.000241	CcSEcCtD
Repaglinide—Rash—Doxorubicin—prostate cancer	3.79e-05	0.000239	CcSEcCtD
Repaglinide—Dermatitis—Doxorubicin—prostate cancer	3.79e-05	0.000239	CcSEcCtD
Repaglinide—Headache—Doxorubicin—prostate cancer	3.77e-05	0.000238	CcSEcCtD
Repaglinide—Nausea—Doxorubicin—prostate cancer	3.57e-05	0.000226	CcSEcCtD
Repaglinide—ALB—Metabolism—SULT2A1—prostate cancer	7.52e-06	7.13e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—MED12—prostate cancer	7.44e-06	7.06e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—MED12—prostate cancer	7.4e-06	7.02e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GNG5—prostate cancer	7.39e-06	7e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—TYMS—prostate cancer	7.38e-06	7e-05	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—PIK3CB—prostate cancer	7.36e-06	6.98e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GNG5—prostate cancer	7.34e-06	6.96e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—GSTM1—prostate cancer	7.3e-06	6.92e-05	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—PTGS2—prostate cancer	7.29e-06	6.91e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	7.22e-06	6.84e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—LPL—prostate cancer	7.16e-06	6.79e-05	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—IL6—prostate cancer	7.16e-06	6.78e-05	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PIK3CB—prostate cancer	7.13e-06	6.76e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NCOA3—prostate cancer	7.11e-06	6.75e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—CREBBP—prostate cancer	7.08e-06	6.71e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NCOA3—prostate cancer	7.07e-06	6.71e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HPGD—prostate cancer	7.07e-06	6.7e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—B4GALT4—prostate cancer	7.07e-06	6.7e-05	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PTGS2—prostate cancer	7.07e-06	6.7e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	6.99e-06	6.63e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—IGF1—prostate cancer	6.99e-06	6.63e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CG—prostate cancer	6.95e-06	6.59e-05	CbGpPWpGaD
Repaglinide—ALB—Platelet activation, signaling and aggregation—PIK3CA—prostate cancer	6.92e-06	6.56e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—CYP1A1—prostate cancer	6.92e-06	6.56e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PIK3CG—prostate cancer	6.88e-06	6.52e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—ERCC2—prostate cancer	6.86e-06	6.5e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—HPGDS—prostate cancer	6.79e-06	6.43e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—HPGDS—prostate cancer	6.75e-06	6.4e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP2C19—prostate cancer	6.74e-06	6.39e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—PIK3CD—prostate cancer	6.71e-06	6.36e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP2C19—prostate cancer	6.71e-06	6.36e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—TNFRSF21—prostate cancer	6.65e-06	6.3e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—SERPINE1—prostate cancer	6.64e-06	6.29e-05	CbGpPWpGaD
Repaglinide—PPARG—Developmental Biology—AKT1—prostate cancer	6.6e-06	6.26e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ACHE—prostate cancer	6.58e-06	6.24e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GSTT1—prostate cancer	6.58e-06	6.24e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GSTT1—prostate cancer	6.55e-06	6.21e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ACHE—prostate cancer	6.55e-06	6.21e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—INS—prostate cancer	6.51e-06	6.18e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP2A6—prostate cancer	6.51e-06	6.17e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	6.48e-06	6.15e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP2A6—prostate cancer	6.47e-06	6.13e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYP7B1—prostate cancer	6.47e-06	6.13e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—MTAP—prostate cancer	6.47e-06	6.13e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—MTHFR—prostate cancer	6.45e-06	6.11e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—CREBBP—prostate cancer	6.44e-06	6.11e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—CREBBP—prostate cancer	6.38e-06	6.05e-05	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—PTEN—prostate cancer	6.36e-06	6.03e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—NOS3—prostate cancer	6.34e-06	6.01e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—AKR1C3—prostate cancer	6.33e-06	6e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PPARA—prostate cancer	6.33e-06	6e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SULT1E1—prostate cancer	6.3e-06	5.98e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SRD5A1—prostate cancer	6.3e-06	5.98e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PRKACB—prostate cancer	6.3e-06	5.97e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—AKR1C3—prostate cancer	6.29e-06	5.97e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PRKACB—prostate cancer	6.26e-06	5.94e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP17A1—prostate cancer	6.23e-06	5.91e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP17A1—prostate cancer	6.2e-06	5.87e-05	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PTEN—prostate cancer	6.16e-06	5.84e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—JAK2—prostate cancer	6.16e-06	5.84e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	6.15e-06	5.83e-05	CbGpPWpGaD
Repaglinide—ALB—Transmembrane transport of small molecules—CREBBP—prostate cancer	6.13e-06	5.81e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CD—prostate cancer	6.11e-06	5.79e-05	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—EP300—prostate cancer	6.06e-06	5.75e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PIK3CD—prostate cancer	6.05e-06	5.74e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ACSL4—prostate cancer	6.01e-06	5.7e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HSD17B3—prostate cancer	6.01e-06	5.7e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—CAV1—prostate cancer	5.95e-06	5.64e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NCOA2—prostate cancer	5.94e-06	5.63e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NCOA2—prostate cancer	5.9e-06	5.6e-05	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—EP300—prostate cancer	5.88e-06	5.57e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—PIK3CB—prostate cancer	5.85e-06	5.55e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ARG2—prostate cancer	5.76e-06	5.47e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PHGDH—prostate cancer	5.76e-06	5.47e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—UMPS—prostate cancer	5.76e-06	5.47e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—NOS3—prostate cancer	5.71e-06	5.42e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	5.68e-06	5.39e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—SLC5A5—prostate cancer	5.66e-06	5.37e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—LDHB—prostate cancer	5.65e-06	5.36e-05	CbGpPWpGaD
Repaglinide—ALB—Platelet activation, signaling and aggregation—AKT1—prostate cancer	5.65e-06	5.36e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—SLC5A5—prostate cancer	5.63e-06	5.34e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYP3A5—prostate cancer	5.55e-06	5.26e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP2E1—prostate cancer	5.53e-06	5.25e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP2E1—prostate cancer	5.5e-06	5.22e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NQO1—prostate cancer	5.47e-06	5.19e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NQO1—prostate cancer	5.44e-06	5.16e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PIK3CG—prostate cancer	5.42e-06	5.14e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—TH—prostate cancer	5.39e-06	5.11e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—IL2—prostate cancer	5.37e-06	5.09e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—TH—prostate cancer	5.36e-06	5.08e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—UCP3—prostate cancer	5.36e-06	5.08e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—TCN2—prostate cancer	5.36e-06	5.08e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PDHA1—prostate cancer	5.36e-06	5.08e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTA3—prostate cancer	5.36e-06	5.08e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	5.36e-06	5.08e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP3A4—prostate cancer	5.33e-06	5.06e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CB—prostate cancer	5.33e-06	5.05e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	5.31e-06	5.03e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP3A4—prostate cancer	5.3e-06	5.03e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PTGS2—prostate cancer	5.28e-06	5e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PIK3CB—prostate cancer	5.27e-06	5e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP1B1—prostate cancer	5.24e-06	4.97e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PTGS2—prostate cancer	5.22e-06	4.95e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP1B1—prostate cancer	5.22e-06	4.94e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—INS—prostate cancer	5.13e-06	4.86e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HSD3B1—prostate cancer	5.11e-06	4.85e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SLC22A3—prostate cancer	5.11e-06	4.85e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GGT1—prostate cancer	5.08e-06	4.82e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GGT1—prostate cancer	5.05e-06	4.79e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—CREBBP—prostate cancer	5.02e-06	4.76e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NCOA1—prostate cancer	5e-06	4.74e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NCOA1—prostate cancer	4.98e-06	4.72e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP19A1—prostate cancer	4.93e-06	4.68e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP19A1—prostate cancer	4.9e-06	4.65e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTA4—prostate cancer	4.9e-06	4.65e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—TBXAS1—prostate cancer	4.9e-06	4.65e-05	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—MYC—prostate cancer	4.87e-06	4.62e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—EP300—prostate cancer	4.82e-06	4.57e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTA2—prostate cancer	4.78e-06	4.53e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PIK3CD—prostate cancer	4.76e-06	4.52e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—RXRA—prostate cancer	4.76e-06	4.51e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—RXRA—prostate cancer	4.73e-06	4.49e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SULT1A1—prostate cancer	4.72e-06	4.47e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ABCG5—prostate cancer	4.72e-06	4.47e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—SRC—prostate cancer	4.69e-06	4.45e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	4.63e-06	4.39e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTA1—prostate cancer	4.61e-06	4.37e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PTEN—prostate cancer	4.6e-06	4.36e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—COMT—prostate cancer	4.58e-06	4.35e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—VEGFA—prostate cancer	4.57e-06	4.33e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GSTP1—prostate cancer	4.56e-06	4.33e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—COMT—prostate cancer	4.56e-06	4.32e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NAT2—prostate cancer	4.56e-06	4.32e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTO1—prostate cancer	4.56e-06	4.32e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HSD3B2—prostate cancer	4.56e-06	4.32e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PTEN—prostate cancer	4.56e-06	4.32e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GSTP1—prostate cancer	4.54e-06	4.3e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—NOS3—prostate cancer	4.5e-06	4.26e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ITPR1—prostate cancer	4.49e-06	4.26e-05	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—PIK3CA—prostate cancer	4.48e-06	4.25e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ITPR1—prostate cancer	4.46e-06	4.23e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—EP300—prostate cancer	4.41e-06	4.19e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—EP300—prostate cancer	4.39e-06	4.16e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYP2C18—prostate cancer	4.37e-06	4.14e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PLCB2—prostate cancer	4.37e-06	4.14e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—LRP2—prostate cancer	4.37e-06	4.14e-05	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—PIK3CA—prostate cancer	4.35e-06	4.12e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—EP300—prostate cancer	4.34e-06	4.12e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—P4HB—prostate cancer	4.28e-06	4.06e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—TYMS—prostate cancer	4.24e-06	4.02e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—TYMS—prostate cancer	4.22e-06	4e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—GSTM1—prostate cancer	4.19e-06	3.98e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—TGFB1—prostate cancer	4.19e-06	3.97e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—GSTM1—prostate cancer	4.17e-06	3.95e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SLC22A1—prostate cancer	4.17e-06	3.95e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PIK3CB—prostate cancer	4.15e-06	3.94e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—LPL—prostate cancer	4.12e-06	3.9e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PTGS2—prostate cancer	4.11e-06	3.9e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—LPL—prostate cancer	4.09e-06	3.88e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SULT2A1—prostate cancer	4.06e-06	3.85e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—MED12—prostate cancer	4e-06	3.79e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CYP1A1—prostate cancer	3.97e-06	3.77e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GNG5—prostate cancer	3.96e-06	3.76e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CYP1A1—prostate cancer	3.95e-06	3.75e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—ERCC2—prostate cancer	3.94e-06	3.74e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—ERCC2—prostate cancer	3.92e-06	3.72e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—KRAS—prostate cancer	3.88e-06	3.68e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NCOA3—prostate cancer	3.82e-06	3.62e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—MTHFR—prostate cancer	3.71e-06	3.51e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—MTHFR—prostate cancer	3.68e-06	3.49e-05	CbGpPWpGaD
Repaglinide—ABCC8—Metabolism—AKT1—prostate cancer	3.66e-06	3.47e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—HPGDS—prostate cancer	3.64e-06	3.45e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PPARA—prostate cancer	3.64e-06	3.45e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYP2C19—prostate cancer	3.62e-06	3.43e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PPARA—prostate cancer	3.61e-06	3.43e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PTEN—prostate cancer	3.59e-06	3.4e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—PIK3CA—prostate cancer	3.57e-06	3.38e-05	CbGpPWpGaD
Repaglinide—KCNJ11—Metabolism—AKT1—prostate cancer	3.55e-06	3.37e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTT1—prostate cancer	3.53e-06	3.35e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ACHE—prostate cancer	3.53e-06	3.35e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYP2A6—prostate cancer	3.49e-06	3.31e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—TP53—prostate cancer	3.45e-06	3.27e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—EP300—prostate cancer	3.42e-06	3.24e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CAV1—prostate cancer	3.42e-06	3.24e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CAV1—prostate cancer	3.4e-06	3.22e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—AKR1C3—prostate cancer	3.4e-06	3.22e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PRKACB—prostate cancer	3.38e-06	3.2e-05	CbGpPWpGaD
Repaglinide—PPARG—Gene Expression—AKT1—prostate cancer	3.38e-06	3.2e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYP17A1—prostate cancer	3.34e-06	3.17e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.27e-06	3.1e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—prostate cancer	3.25e-06	3.08e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—PIK3CA—prostate cancer	3.21e-06	3.05e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NCOA2—prostate cancer	3.19e-06	3.02e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PIK3CG—prostate cancer	3.11e-06	2.95e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PIK3CG—prostate cancer	3.1e-06	2.94e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—SLC5A5—prostate cancer	3.04e-06	2.88e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYP2E1—prostate cancer	2.97e-06	2.82e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—INS—prostate cancer	2.95e-06	2.79e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NQO1—prostate cancer	2.94e-06	2.78e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—INS—prostate cancer	2.93e-06	2.78e-05	CbGpPWpGaD
Repaglinide—ALB—Hemostasis—AKT1—prostate cancer	2.91e-06	2.76e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—TH—prostate cancer	2.89e-06	2.74e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—CREBBP—prostate cancer	2.89e-06	2.74e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—CREBBP—prostate cancer	2.87e-06	2.72e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYP1B1—prostate cancer	2.82e-06	2.67e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PIK3CD—prostate cancer	2.74e-06	2.6e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GGT1—prostate cancer	2.73e-06	2.59e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PIK3CD—prostate cancer	2.72e-06	2.58e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NCOA1—prostate cancer	2.69e-06	2.55e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYP19A1—prostate cancer	2.65e-06	2.51e-05	CbGpPWpGaD
Repaglinide—PPARG—Metabolism—AKT1—prostate cancer	2.63e-06	2.49e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—NOS3—prostate cancer	2.58e-06	2.45e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—NOS3—prostate cancer	2.57e-06	2.44e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—RXRA—prostate cancer	2.55e-06	2.42e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—PIK3CA—prostate cancer	2.53e-06	2.4e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—COMT—prostate cancer	2.46e-06	2.33e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTP1—prostate cancer	2.45e-06	2.32e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ITPR1—prostate cancer	2.41e-06	2.28e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PIK3CB—prostate cancer	2.39e-06	2.26e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PIK3CB—prostate cancer	2.37e-06	2.25e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PTGS2—prostate cancer	2.36e-06	2.24e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PTGS2—prostate cancer	2.35e-06	2.23e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—TYMS—prostate cancer	2.28e-06	2.16e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—GSTM1—prostate cancer	2.25e-06	2.13e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—LPL—prostate cancer	2.21e-06	2.09e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CYP1A1—prostate cancer	2.13e-06	2.02e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—ERCC2—prostate cancer	2.12e-06	2.01e-05	CbGpPWpGaD
Repaglinide—SLCO1B1—Metabolism—AKT1—prostate cancer	2.07e-06	1.96e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PTEN—prostate cancer	2.06e-06	1.95e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PTEN—prostate cancer	2.05e-06	1.94e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—MTHFR—prostate cancer	1.99e-06	1.89e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—EP300—prostate cancer	1.97e-06	1.86e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—EP300—prostate cancer	1.95e-06	1.85e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PPARA—prostate cancer	1.95e-06	1.85e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CAV1—prostate cancer	1.83e-06	1.74e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PIK3CG—prostate cancer	1.67e-06	1.58e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—INS—prostate cancer	1.58e-06	1.5e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—CREBBP—prostate cancer	1.55e-06	1.47e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PIK3CD—prostate cancer	1.47e-06	1.39e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—PIK3CA—prostate cancer	1.45e-06	1.38e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—PIK3CA—prostate cancer	1.45e-06	1.37e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—NOS3—prostate cancer	1.39e-06	1.32e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PIK3CB—prostate cancer	1.28e-06	1.21e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PTGS2—prostate cancer	1.27e-06	1.2e-05	CbGpPWpGaD
Repaglinide—CYP2C8—Metabolism—AKT1—prostate cancer	1.19e-06	1.13e-05	CbGpPWpGaD
Repaglinide—ALB—Metabolism—AKT1—prostate cancer	1.18e-06	1.12e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PTEN—prostate cancer	1.11e-06	1.05e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—EP300—prostate cancer	1.06e-06	1e-05	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—PIK3CA—prostate cancer	7.81e-07	7.4e-06	CbGpPWpGaD
Repaglinide—CYP3A4—Metabolism—AKT1—prostate cancer	6.38e-07	6.05e-06	CbGpPWpGaD
